Wired
April 18, 2025
Syntis Bio, a spinout from the Langer and Traverso labs, has announced promising early data for its obesity pill, which mimics the effects of a gastric bypass surgery via a temporary coating in the upper intestine. Interest in controlling obesity has surged as research uncovers its roles in cancer and other diseases, and the new pill is aimed at offering more effective and personalized choices for patients.